Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 1.00 |
| ▸ | WNT3A | P56704 | 5/20 | 0.62 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587173 | 0.94 | MET (0.89) | METWNT3ACSNK1DCSF1RPDGFRB | |
| SCHEMBL2189472 | 0.93 | MET (0.87) | METWNT3AKITPDGFRACSNK1D | |
| SCHEMBL4373367 | 0.88 | MET (0.79) | METWNT3ACSNK1DCYP3A4 | |
| SCHEMBL4378672 | 0.87 | MET (0.78) | METWNT3APDGFRACSNK1DCSF1R | |
| SCHEMBL4371744 | 0.87 | MET (0.77) | METWNT3ACSNK1DCSF1RPDGFRB | |
| SCHEMBL4368604 | 0.87 | MET (0.77) | METKITPDGFRAKDR | |
| SCHEMBL371825 | 0.86 | MET (0.76) | METWNT3AKITPDGFRACSNK1D | |
| SCHEMBL13587156 | 0.86 | MET (0.75) | METWNT3ACSNK1DCSF1RPDGFRB | |
| SCHEMBL4381327 | 0.85 | MET (0.73) | METPDGFRAPDGFRBKDR | |
| SCHEMBL13587157 | 0.84 | MET (0.73) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | claimed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | claimed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | claimed |
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | claimed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | claimed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |
| US-20060142570-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-29 | — | — | US | claimed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | AMGEN INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885WNT3A 820/4885KIT 5/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885WNT3A 820/4885KIT 5/4885 |
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885WNT3A 915/4885KIT 4/4885 |
| US-20060142570-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | MET 4526/4885WNT3A 3093/4885KIT 2079/4885 |
| US-20110172241-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | MET 4526/4885WNT3A 3093/4885KIT 2079/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885WNT3A 820/4885KIT 5/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885WNT3A 820/4885KIT 5/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MET 3/4885WNT3A 820/4885KIT 5/4885 |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | CYP3A5, CYP3A7, CYP3A43 | MET 4512/4885WNT3A 2960/4885KIT 2088/4885 |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | HGF, MET, HGFAC | MET 2/4885WNT3A 1795/4885KIT 174/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885WNT3A 915/4885KIT 4/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885WNT3A 820/4885KIT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.